Metastatic Melanoma 2024 x Dr. Mike Atkins Part 2

Dr. Michael Atkins, a leading authority in metastatic melanoma and first author of the pioneering DREAMseq trial, delves into cutting-edge treatment options. He shares an inspiring case of an elderly patient and how immunotherapy can lead to rapid tumor regression. Discussion includes the impact of advanced therapies like BRAF-MEK inhibitors and the new Relatlimab-Nivolumab combination. Insights on treating brain metastases emphasize the need for teamwork in decision-making. Atkins also covers strategies for various melanoma subtypes and offers advice for budding oncologists.